Friday's top analyst upgrades, downgrades and initiations include Abbott Labs, BioMarin Pharmaceutical, CBS, Cisco, GameStop, Petrobras, Sirius XM, SunPower and Yelp.
These four top large cap biotechs are very good bets for investors looking to add high-quality companies with less volatility and binary clinical data risk.
A report on Wednesday from Janney Capital Markets has targeted several iotech bcompanies it believes are now grossly oversold.
In a recent research report, Jefferies highlighted three top biotech companies that are very tempting buys now.
Now is the time to really review portfolios and replace momentum winners with earnings growth leaders. The Cowen Focus Call stocks are just the ticket.
SunTrust Robinson Humphrey handicaps some of the upcoming events for stocks in the firm's coverage universe that have potential market-moving clinical and FDA catalysts during the remainder of 2015.
Lee Jackson A new research report from Cowen focuses on the top biotech stocks to buy before second-quarter earnings are reported.
Friday's top analyst upgrades, downgrades and initiations include BioMarin Pharmaceuticals, BP, Micron Technology, Vonage, Finisar, Consolidated Edison and Red Hat.
BioMarin Pharmaceutical has three key drivers helping out its shares on Thursday: drug news, analyst support, record high Nasdaq.
Jon C. Ogg A recent research piece from the analysts at Jefferies presents the firm's four top growth stock calls for this holiday-shortened trading week.
A new research note from SunTrust Robinson Humphrey mentions four stocks that they think could possibly get swept up in the biotech M&A excitement.
In a new report, Deutsche Bank acknowledges that while the industry has shown recent weakness, now may be just the right time to add biotech stocks.
In a new report from RBC, while they think the selling and profit taking in biotechs could go on, they also hold fast that industry fundamentals are still very positive.
Wells Fargo released a report Wednesday that considers the future of major biotech companies in relation to the weak euro.
Here are three biotech stocks that a SunTrust analyst feels could be buyout candidates, in the wake of the Pharmacyclics acquisition.
